AstraZeneca (LON:AZN) Hits New 52-Week Low – What’s Next?

AstraZeneca PLC (LON:AZN)’s share price hit a new 52-week low on Wednesday. The stock traded as low as GBX 119.20 and last traded at £119.86, with a volume of 38668527 shares. The stock had previously closed at £119.58.

Trending Headlines about AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Analyst support remains strong: Jefferies reaffirmed its “buy” rating and set a £175 price target, while Berenberg also maintained a “buy” rating with a £175 target. Citi separately raised its target to 18,600 pence (£186), implying substantial upside from recent trading levels. Jefferies maintains buy rating Citi raises AstraZeneca target
• Positive Sentiment: Oncology pipeline strengthened: AstraZeneca’s investment in Summit Therapeutics is deepening its cancer pipeline and expanding its exposure to potentially important oncology programs. AstraZeneca Summit Therapeutics investment
• Positive Sentiment: Prostate-cancer collaboration: AstraZeneca is partnering with Myriad Genetics and SOPHiA GENETICS on prostate-cancer polygenic risk scores, a move that could support more personalized patient identification and treatment decisions. Prostate cancer risk-score partnership
• Neutral Sentiment: Market positioning: AstraZeneca was reported at about €142.63 with an approximately $248.3 billion market capitalization, underscoring its scale but offering limited new information for valuation. AstraZeneca market capitalization
• Negative Sentiment: Recent trading weakness: AstraZeneca fell and underperformed the broader market, while a separate report noted that the shares reached a new 12-month low. The decline suggests near-term selling pressure is outweighing favorable broker commentary and pipeline news. AstraZeneca underperforms market AstraZeneca reaches 12-month low

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Jefferies Financial Group restated a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a research report on Wednesday. Berenberg Bank restated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a research note on Wednesday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 price objective on shares of AstraZeneca in a research report on Tuesday, September 29th. Royal Bank Of Canada restated an “outperform” rating and set a £145 target price on shares of AstraZeneca in a research report on Tuesday, September 8th. Finally, Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of £153.57.

AstraZeneca Price Performance

The stock’s 50 day moving average price is £120.57 and its 200-day moving average price is £132.06. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The stock has a market capitalization of £186.70 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Michel Demare bought 2,500 shares of the business’s stock in a transaction on Monday, September 14th. The shares were acquired at an average price of £121.21 per share, with a total value of £303,025. 0.15% of the stock is currently owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.